Towards antibody-based immunotherapy development for platinum-resistant high-grade serous ovarian cancer.

ABSTRACT: Epithelial ovarian cancer is the sixth most common malignant neoplasm in women and the leading cause of death from gynecological malignancies in the Western World. The five-year survival rate is 45-48% because of the high frequency of late-stage diagnoses and the development of chemo-resistant disease. To assess the potential of antibodies and complement to kill platinum (Pt)-resistant and Pt-sensitive cell lines, antibodies S2 and Yth53.1 were tested at varying concentrations using high-grade serous ovarian cancer (HGSOC) cells. Cell lysis was quantified after 60 minutes using the impermeant dyes 7-Aminoactinomycin D and Annexin V. The cytotoxic effect of S2 was demonstrated through the activation of the complement and Yth53.1 monoclonal antibody neutralized the membrane attack complex (M

SUBMITTER: Giedraityte Z 

PROVIDER: S-EPMC12701068 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature